Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 1...
Saved in:
| Published in | Scientific Reports Vol. 11; no. 1; pp. 4875 - 9 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Springer Science and Business Media LLC
01.03.2021
Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2045-2322 2045-2322 |
| DOI | 10.1038/s41598-021-83999-z |
Cover
| Abstract | Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value. |
|---|---|
| AbstractList | Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value. Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value. Abstract Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value. Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value.Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of treatment with sulfonylureas (SUs) in type 2 diabetes mellitus (T2DM) with well-controlled glucose level (TIR > 70%). The study subjects were 123 patients selected T2DM who underwent CGM more than 24 h on admission without changing treatment. The primary endpoint was the difference in glycemic variability, while the secondary endpoint was the difference in time below range < 54 mg/dL; TBR < 54, between the SU (n = 63) and non-SU (n = 60) groups. The standard deviation, percentage coefficient of variation (%CV), and maximum glucose level were higher in the SU group than in the non-SU group, and TBR < 54 was longer in the high-dose SU patients. SU treatment was identified as a significant factor that affected %CV (β: 2.678, p = 0.034). High-dose SU use contributed to prolonged TBR < 54 (β: 0.487, p = 0.028). Our study identified enlarged glycemic variability in sulfonylurea-treated well-controlled T2DM patients and high-dose SU use was associated with TBR < 54. The results highlight the need for careful adjustment of the SU dose, irrespective of glycated hemoglobin level or TIR value. |
| ArticleNumber | 4875 |
| Author | Keiichi Torimoto Fumi Uemura Yoshiya Tanaka Yosuke Okada |
| Author_xml | – sequence: 1 givenname: Fumi surname: Uemura fullname: Uemura, Fumi organization: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan – sequence: 2 givenname: Yosuke surname: Okada fullname: Okada, Yosuke organization: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan – sequence: 3 givenname: Keiichi surname: Torimoto fullname: Torimoto, Keiichi organization: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan – sequence: 4 givenname: Yoshiya surname: Tanaka fullname: Tanaka, Yoshiya email: tanaka@med.uoeh-u.ac.jp organization: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan |
| BackLink | https://cir.nii.ac.jp/crid/1872835442374959744$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/33649395$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vFSEUnZgaW2v_gAsziS7cjPI5AxsT01Rt0sSNrgkwd540PHgCU_O693_LdGqtXXQDXO45h8u953lzEGKApnmJ0TuMqHifGeZSdIjgTlApZXf9pDkiiPGOUEIO7p0Pm5OcnakhxRIJ9Kw5pLRnkkp-1Pw-C16nDYztxu8tbJ1tr3Ry2jjvyr51oc2zn2LY-zmB7kpdSgX_Au87G0NJ0fsal_0OWtKOlQjF2dy6EUJxk6u5ObuwaRewC3Occ31ptjFDu43BlZhq9kXzdNI-w8ntftx8_3T27fRLd_H18_npx4vO9oKWjhs6MD4S0Wsj8EBHygc-gaTcTIaiYWI95T0lHFlJgHIw04RHqaGypBVAj5vzVXeM-lLtktvqtFdRO3VzEdNG6VTr96CMIYYSZAYzIGZGbIBTjZAwIBnvOa9aH1at3Wy2MNr636T9f6L_Z4L7oTbxSg2SYM5RFXh7K5DizxlyUVuXbW2sDlDbpAiTnKGBcFGhrx9AL-OcQm3VgmIDkj0iFfXqfkV3pfyddgWQFWBTzDnBdAfBSC2uUqurVHWVunGVuq4k8YBkXdHFLcPXzj9OpSs175YpQ_pX9qOsNysrOFffWlYsBiIoZ4xUA0guB8boH8hn71o |
| CitedBy_id | crossref_primary_10_1111_dom_14550 crossref_primary_10_2147_IJGM_S477497 crossref_primary_10_1089_dia_2021_0465 crossref_primary_10_1016_j_diabres_2023_110718 crossref_primary_10_17925_EE_2023_19_2_4 crossref_primary_10_1038_s41574_024_00973_1 crossref_primary_10_3390_nu13114052 |
| Cites_doi | 10.1016/j.diabet.2017.10.005 10.1089/dia.2017.0306 10.2337/dc16-1769 10.1111/j.2040-1124.2010.00074.x 10.1111/jan.13765 10.1111/jdi.12778 10.1111/jdi.13132 10.1016/j.diabet.2019.01.012 10.1093/sleep/zsy071 10.1111/jdi.12645 10.1089/dia.2018.0017 10.2337/dc10-0115 10.1007/s13300-018-0492-3 10.1111/jdi.13336 10.1016/S0140-6736(98)07019-6 10.1001/jamainternmed.2016.2275 10.1186/s13098-019-0412-3 10.1016/j.jdiacomp.2016.12.014 10.2337/dc10-1989 10.2337/dc16-1972 10.1210/jc.2012-4127 10.1111/dom.12449 10.2337/dc18-1444 10.1111/jdi.13160 10.1016/j.diabet.2018.02.008 10.2337/diacare.13.2.133 10.2337/diabetes.52.11.2790 10.2337/dci19-0028 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | RYH C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-021-83999-z |
| DatabaseName | CiNii Complete Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_bb2b320b7b704bd1be53a008be945655 PMC7921550 33649395 10_1038_s41598_021_83999_z |
| Genre | Journal Article |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M48 M7P M~E NAO OK1 PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM RYH SNYQT UKHRP 3V. 88A ACSMW AJTQC M0L AAYXX CITATION NPM 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c683t-5b3745d286ab8173d3575fe935bfb307f463563250c92e35ebff1d9ae7459c8e3 |
| IEDL.DBID | 7X7 |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 00:48:35 EDT 2025 Thu Aug 21 13:32:59 EDT 2025 Fri Sep 05 11:18:49 EDT 2025 Wed Aug 13 08:08:48 EDT 2025 Thu Jan 02 22:57:10 EST 2025 Tue Jul 01 01:07:35 EDT 2025 Thu Apr 24 22:55:37 EDT 2025 Fri Feb 21 02:39:01 EST 2025 Fri Jun 27 00:49:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c683t-5b3745d286ab8173d3575fe935bfb307f463563250c92e35ebff1d9ae7459c8e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-5174-5980 |
| OpenAccessLink | https://www.proquest.com/docview/2494709602?pq-origsite=%requestingapplication% |
| PMID | 33649395 |
| PQID | 2494709602 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bb2b320b7b704bd1be53a008be945655 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7921550 proquest_miscellaneous_2495407258 proquest_journals_2494709602 pubmed_primary_33649395 crossref_primary_10_1038_s41598_021_83999_z crossref_citationtrail_10_1038_s41598_021_83999_z springer_journals_10_1038_s41598_021_83999_z nii_cinii_1872835442374959744 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific Reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2021 |
| Publisher | Springer Science and Business Media LLC Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Springer Science and Business Media LLC – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | UemuraFOkadaYTorimotoKTanakaYRelation between hypoglycemia and glycemic variability in type 2 diabetes patients with insulin therapy: A study based on continuous glucose monitoringDiabetes Technol. Ther.2018201401461:CAS:528:DC%2BC1cXhs1Oju70%3D10.1089/dia.2017.0306 FestaAHellerSRSeaquistEDuanRHadjiyianniIFuHAssociation between mild and severe hypoglycemia in people with type 2 diabetes mellitus initiating insulinJ. Diabetes Complications2017311047105210.1016/j.jdiacomp.2016.12.014 KurodaNRelationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications studyJ. Diabetes Investig.202010.1111/jdi.13336330981917858127 HirschIBFailure of nocturnal hypoglycemia to cause daytime hyperglycemia in patients with IDDMDiabetes Care1990131331421:STN:280:DyaK3c3ns1Whug%3D%3D10.2337/diacare.13.2.133 LiFMale patients with longstanding type 2 diabetes have a higher incidence of hypoglycemia compared with female patientsDiabetes Ther.20189196919771:CAS:528:DC%2BC1cXhsFOjsrvE10.1007/s13300-018-0492-3 The committee on the proper use of SGLT2 inhibitors. Recommendations on the proper use of SGLT2 inhibitors. J. Diabetes Investig.11, 257–261 (2020). MatsuokaARelationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional studyJ. Diabetes Investig.20191141742510.1111/jdi.13132 MonnierLColetteCOwensDThe application of simple metrics in the assessment of glycaemic variabilityDiabetes Metab.2018443133191:CAS:528:DC%2BC1cXlt1Ojsbs%3D10.1016/j.diabet.2018.02.008 Matsumoto, T., et al. Impact of sleep characteristics and obesity on diabetes and hypertension across genders and menopausal status: the Nagahama study. Sleep41, zsy071. https://doi.org/10.1093/sleep/zsy071 (2018). BoyneMSSilverDMKaplanJSaudekCDTiming of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensorDiabetes200352279027941:CAS:528:DC%2BD3sXovVagtLw%3D10.2337/diabetes.52.11.2790 SeinoYReport of the committee on the classification and diagnostic criteria of diabetes mellitusJ. Diabetes Investig.2010121222810.1111/j.2040-1124.2010.00074.x BenaliaMGlycemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarctionDiabetes Metab2019454464521:CAS:528:DC%2BC1MXjsVGhsbg%3D10.1016/j.diabet.2019.01.012 TorimotoKOkadaYHajimeMTanakaKTanakaYRisk factors of hypoglycemia in patients with type 2 diabetes mellitus: A study based on continuous glucose monitoringDiabetes Technol. Ther.2018206036121:CAS:528:DC%2BC1cXhsFyksbnO10.1089/dia.2018.0017 Martyn-NemethPPoor sleep quality is associated with nocturnal glycaemic variability and fear of hypoglycaemia in adults with type 1 diabetesJ. Adv. Nurs.2018742373238010.1111/jan.13765 BattelinoTEffect of continuous glucose monitoring on hypoglycemia in type 1 diabetesDiabetes Care20113479580010.2337/dc10-1989 NakamuraJCauses of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report from the committee on the cause of death in diabetes mellitusJ. Diabetes Investig.201783974101:CAS:528:DC%2BC2sXntVGgu7c%3D10.1111/jdi.12645 BeckRWValidation of time in range as an outcome measure for diabetes clinical trialsDiabetes Care2019424004051:CAS:528:DC%2BC1MXhs1WgtrnJ10.2337/dc18-1444 IkedaYKuboTOdaEAbeMTokitaSIncidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysisJ. Diabetes Investig.201899259361:CAS:528:DC%2BC1cXht1yjsrrI10.1111/jdi.12778 SeaquistERHypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine SocietyJ. Clin. Endocrinol. Metab.201398184518591:CAS:528:DC%2BC3sXotl2nsb8%3D10.1210/jc.2012-4127 Kautzky-WillerAKosiLLinJMihaljevicRGender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes mellitus: Results from patient-level pooled data of six randomized controlled trialsDiabetes Obes. Metab.2015175335401:CAS:528:DC%2BC2MXntFGgsLs%3D10.1111/dom.12449 McCoyRGLipskaKJYaoXRossJSMontoriVMShahNDIntensive treatment and severe hypoglycemia among adults with type 2 diabetesJAMA Intern. Med.201617696997810.1001/jamainternmed.2016.2275 United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet352, 837–853 (1998). MonnierLColetteCOwensDGlucose variability: Do we have to revisit the profusion of definitions to avoid confusion?Diabetes Metab.201844971001:STN:280:DC%2BC1M3islyjtw%3D%3D10.1016/j.diabet.2017.10.005 Hajime, M., et al. Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. Diabetol. Metab. Syndr11, 18. https://doi.org/10.1186/s13098-019-0412-3 (2019). MonnierLToward defining the threshold between low and high glucose variability in diabetesDiabetes Care2017408328381:CAS:528:DC%2BC1cXhvFGjt7fM10.2337/dc16-1769 BattelinoTClinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in rangeDiabetes Care2019421593160310.2337/dci19-0028 MiddletonTLCardiac effects of sulfonylurea-related hypoglycemiaDiabetes Care2017406636701:CAS:528:DC%2BC1cXptVOgtb0%3D10.2337/dc16-1972 FrancSCan Postprandial blood glucose excursion be predicted in type 2 diabetes?Diabetes Care201033191319181:CAS:528:DC%2BC3cXht1OmurjJ10.2337/dc10-0115 F Li (83999_CR25) 2018; 9 K Torimoto (83999_CR6) 2018; 20 L Monnier (83999_CR14) 2018; 44 P Martyn-Nemeth (83999_CR21) 2018; 74 83999_CR12 83999_CR1 83999_CR7 IB Hirsch (83999_CR23) 1990; 13 S Franc (83999_CR22) 2010; 33 A Matsuoka (83999_CR19) 2019; 11 Y Ikeda (83999_CR13) 2018; 9 ER Seaquist (83999_CR4) 2013; 98 F Uemura (83999_CR17) 2018; 20 L Monnier (83999_CR15) 2018; 44 MS Boyne (83999_CR10) 2003; 52 A Festa (83999_CR26) 2017; 31 RW Beck (83999_CR9) 2019; 42 TL Middleton (83999_CR2) 2017; 40 RG McCoy (83999_CR27) 2016; 176 Y Seino (83999_CR11) 2010; 1 J Nakamura (83999_CR3) 2017; 8 N Kuroda (83999_CR28) 2020 T Battelino (83999_CR5) 2011; 34 A Kautzky-Willer (83999_CR24) 2015; 17 83999_CR20 L Monnier (83999_CR18) 2017; 40 M Benalia (83999_CR16) 2019; 45 T Battelino (83999_CR8) 2019; 42 |
| References_xml | – reference: The committee on the proper use of SGLT2 inhibitors. Recommendations on the proper use of SGLT2 inhibitors. J. Diabetes Investig.11, 257–261 (2020). – reference: BattelinoTEffect of continuous glucose monitoring on hypoglycemia in type 1 diabetesDiabetes Care20113479580010.2337/dc10-1989 – reference: MonnierLColetteCOwensDGlucose variability: Do we have to revisit the profusion of definitions to avoid confusion?Diabetes Metab.201844971001:STN:280:DC%2BC1M3islyjtw%3D%3D10.1016/j.diabet.2017.10.005 – reference: BenaliaMGlycemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarctionDiabetes Metab2019454464521:CAS:528:DC%2BC1MXjsVGhsbg%3D10.1016/j.diabet.2019.01.012 – reference: SeinoYReport of the committee on the classification and diagnostic criteria of diabetes mellitusJ. Diabetes Investig.2010121222810.1111/j.2040-1124.2010.00074.x – reference: Martyn-NemethPPoor sleep quality is associated with nocturnal glycaemic variability and fear of hypoglycaemia in adults with type 1 diabetesJ. Adv. Nurs.2018742373238010.1111/jan.13765 – reference: HirschIBFailure of nocturnal hypoglycemia to cause daytime hyperglycemia in patients with IDDMDiabetes Care1990131331421:STN:280:DyaK3c3ns1Whug%3D%3D10.2337/diacare.13.2.133 – reference: MonnierLToward defining the threshold between low and high glucose variability in diabetesDiabetes Care2017408328381:CAS:528:DC%2BC1cXhvFGjt7fM10.2337/dc16-1769 – reference: Hajime, M., et al. Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. Diabetol. Metab. Syndr11, 18. https://doi.org/10.1186/s13098-019-0412-3 (2019). – reference: Matsumoto, T., et al. Impact of sleep characteristics and obesity on diabetes and hypertension across genders and menopausal status: the Nagahama study. Sleep41, zsy071. https://doi.org/10.1093/sleep/zsy071 (2018). – reference: UemuraFOkadaYTorimotoKTanakaYRelation between hypoglycemia and glycemic variability in type 2 diabetes patients with insulin therapy: A study based on continuous glucose monitoringDiabetes Technol. Ther.2018201401461:CAS:528:DC%2BC1cXhs1Oju70%3D10.1089/dia.2017.0306 – reference: FrancSCan Postprandial blood glucose excursion be predicted in type 2 diabetes?Diabetes Care201033191319181:CAS:528:DC%2BC3cXht1OmurjJ10.2337/dc10-0115 – reference: United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet352, 837–853 (1998). – reference: IkedaYKuboTOdaEAbeMTokitaSIncidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysisJ. Diabetes Investig.201899259361:CAS:528:DC%2BC1cXht1yjsrrI10.1111/jdi.12778 – reference: NakamuraJCauses of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report from the committee on the cause of death in diabetes mellitusJ. Diabetes Investig.201783974101:CAS:528:DC%2BC2sXntVGgu7c%3D10.1111/jdi.12645 – reference: FestaAHellerSRSeaquistEDuanRHadjiyianniIFuHAssociation between mild and severe hypoglycemia in people with type 2 diabetes mellitus initiating insulinJ. Diabetes Complications2017311047105210.1016/j.jdiacomp.2016.12.014 – reference: LiFMale patients with longstanding type 2 diabetes have a higher incidence of hypoglycemia compared with female patientsDiabetes Ther.20189196919771:CAS:528:DC%2BC1cXhsFOjsrvE10.1007/s13300-018-0492-3 – reference: BeckRWValidation of time in range as an outcome measure for diabetes clinical trialsDiabetes Care2019424004051:CAS:528:DC%2BC1MXhs1WgtrnJ10.2337/dc18-1444 – reference: Kautzky-WillerAKosiLLinJMihaljevicRGender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes mellitus: Results from patient-level pooled data of six randomized controlled trialsDiabetes Obes. Metab.2015175335401:CAS:528:DC%2BC2MXntFGgsLs%3D10.1111/dom.12449 – reference: KurodaNRelationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications studyJ. Diabetes Investig.202010.1111/jdi.13336330981917858127 – reference: MonnierLColetteCOwensDThe application of simple metrics in the assessment of glycaemic variabilityDiabetes Metab.2018443133191:CAS:528:DC%2BC1cXlt1Ojsbs%3D10.1016/j.diabet.2018.02.008 – reference: TorimotoKOkadaYHajimeMTanakaKTanakaYRisk factors of hypoglycemia in patients with type 2 diabetes mellitus: A study based on continuous glucose monitoringDiabetes Technol. Ther.2018206036121:CAS:528:DC%2BC1cXhsFyksbnO10.1089/dia.2018.0017 – reference: MiddletonTLCardiac effects of sulfonylurea-related hypoglycemiaDiabetes Care2017406636701:CAS:528:DC%2BC1cXptVOgtb0%3D10.2337/dc16-1972 – reference: SeaquistERHypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine SocietyJ. Clin. Endocrinol. Metab.201398184518591:CAS:528:DC%2BC3sXotl2nsb8%3D10.1210/jc.2012-4127 – reference: MatsuokaARelationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional studyJ. Diabetes Investig.20191141742510.1111/jdi.13132 – reference: BoyneMSSilverDMKaplanJSaudekCDTiming of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensorDiabetes200352279027941:CAS:528:DC%2BD3sXovVagtLw%3D10.2337/diabetes.52.11.2790 – reference: BattelinoTClinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in rangeDiabetes Care2019421593160310.2337/dci19-0028 – reference: McCoyRGLipskaKJYaoXRossJSMontoriVMShahNDIntensive treatment and severe hypoglycemia among adults with type 2 diabetesJAMA Intern. Med.201617696997810.1001/jamainternmed.2016.2275 – volume: 44 start-page: 97 year: 2018 ident: 83999_CR14 publication-title: Diabetes Metab. doi: 10.1016/j.diabet.2017.10.005 – volume: 20 start-page: 140 year: 2018 ident: 83999_CR17 publication-title: Diabetes Technol. Ther. doi: 10.1089/dia.2017.0306 – volume: 40 start-page: 832 year: 2017 ident: 83999_CR18 publication-title: Diabetes Care doi: 10.2337/dc16-1769 – volume: 1 start-page: 212 year: 2010 ident: 83999_CR11 publication-title: J. Diabetes Investig. doi: 10.1111/j.2040-1124.2010.00074.x – volume: 74 start-page: 2373 year: 2018 ident: 83999_CR21 publication-title: J. Adv. Nurs. doi: 10.1111/jan.13765 – volume: 9 start-page: 925 year: 2018 ident: 83999_CR13 publication-title: J. Diabetes Investig. doi: 10.1111/jdi.12778 – volume: 11 start-page: 417 year: 2019 ident: 83999_CR19 publication-title: J. Diabetes Investig. doi: 10.1111/jdi.13132 – volume: 45 start-page: 446 year: 2019 ident: 83999_CR16 publication-title: Diabetes Metab doi: 10.1016/j.diabet.2019.01.012 – ident: 83999_CR20 doi: 10.1093/sleep/zsy071 – volume: 8 start-page: 397 year: 2017 ident: 83999_CR3 publication-title: J. Diabetes Investig. doi: 10.1111/jdi.12645 – volume: 20 start-page: 603 year: 2018 ident: 83999_CR6 publication-title: Diabetes Technol. Ther. doi: 10.1089/dia.2018.0017 – volume: 33 start-page: 1913 year: 2010 ident: 83999_CR22 publication-title: Diabetes Care doi: 10.2337/dc10-0115 – volume: 9 start-page: 1969 year: 2018 ident: 83999_CR25 publication-title: Diabetes Ther. doi: 10.1007/s13300-018-0492-3 – year: 2020 ident: 83999_CR28 publication-title: J. Diabetes Investig. doi: 10.1111/jdi.13336 – ident: 83999_CR1 doi: 10.1016/S0140-6736(98)07019-6 – volume: 176 start-page: 969 year: 2016 ident: 83999_CR27 publication-title: JAMA Intern. Med. doi: 10.1001/jamainternmed.2016.2275 – ident: 83999_CR7 doi: 10.1186/s13098-019-0412-3 – volume: 31 start-page: 1047 year: 2017 ident: 83999_CR26 publication-title: J. Diabetes Complications doi: 10.1016/j.jdiacomp.2016.12.014 – volume: 34 start-page: 795 year: 2011 ident: 83999_CR5 publication-title: Diabetes Care doi: 10.2337/dc10-1989 – volume: 40 start-page: 663 year: 2017 ident: 83999_CR2 publication-title: Diabetes Care doi: 10.2337/dc16-1972 – volume: 98 start-page: 1845 year: 2013 ident: 83999_CR4 publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2012-4127 – volume: 17 start-page: 533 year: 2015 ident: 83999_CR24 publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.12449 – volume: 42 start-page: 400 year: 2019 ident: 83999_CR9 publication-title: Diabetes Care doi: 10.2337/dc18-1444 – ident: 83999_CR12 doi: 10.1111/jdi.13160 – volume: 44 start-page: 313 year: 2018 ident: 83999_CR15 publication-title: Diabetes Metab. doi: 10.1016/j.diabet.2018.02.008 – volume: 13 start-page: 133 year: 1990 ident: 83999_CR23 publication-title: Diabetes Care doi: 10.2337/diacare.13.2.133 – volume: 52 start-page: 2790 year: 2003 ident: 83999_CR10 publication-title: Diabetes doi: 10.2337/diabetes.52.11.2790 – volume: 42 start-page: 1593 year: 2019 ident: 83999_CR8 publication-title: Diabetes Care doi: 10.2337/dci19-0028 |
| SSID | ssib045319080 ssib045319113 ssib045318930 ssib045319110 ssib045318929 ssib045318928 ssj0000529419 ssib045319075 |
| Score | 2.362552 |
| Snippet | Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability of... Abstract Time in range (TIR) is an index of glycemic control obtained from continuous glucose monitoring (CGM). The aim was to compare the glycemic variability... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4875 |
| SubjectTerms | 692/163/2743/137 692/163/2743/137/773 Aged Blood Glucose Blood Glucose Self-Monitoring Coefficient of variation Cross-Sectional Studies Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 Female Glucose Glucose monitoring Hemoglobin Humanities and Social Sciences Humans Hypoglycemic Agents Medicine Middle Aged multidisciplinary Q R Science Science (multidisciplinary) Sulfonylurea Sulfonylurea Compounds |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDeBFhmJG1hN_IjtI6BWFRKcqNRblImdEmlJK7KLtL3zv5mxs0uX54XLSllPlIlnHM_Yn79h7IUNFLR3VhjjPCUovYBovbCur30A5TpPB4Xff6hPTvW7M3N2rdQXYcIyPXDuuEMACUqWYMGWGkIF0agWJy6InoKRxF5a-vJaMpVZvaXXlZ9PyZTKHU44U9FpMlkJjAm8F1c7M1Ei7Mf5ZRyG38Wav0Imf9o3TdPR8R12e44j-eus_112I4732M1cWXJ9n307GheE8Q78fLHuCADPv2JWnEm513wY-bRa9BtUukhwcxSmlTwxo9cXeE0LtFzyvEA7dBMfQkYXYRsh5s85CQ_j6mI18Rn9zj-nzwSp_YCdHh99fHsi5ooLoqudWgoDymoTpKtbcJVVQWE010evDPSAX4NeE52dwrCp8zIqE6Hvq-DbiHf5zkX1kO2NF2N8zHgVoQUTVdkBaE-VQJ1yZYh1qHsJEQpWbXq_6WY6cqqKsWjStrhyTbZYgxZrksWaq4K93N5zmck4_ir9hoy6lSQi7fQHulczu1fzL_cq2AG6BGpIv5WzRE-nCUqEiSWmYrpg-xtnaebRPzWY0mpLuaEs2PNtM45b2oxpx4g2IRniPpTGFexR9q2tpkrV2iuPD7c7XrfzKrst4_ApcYNbLynpLNirjX_-UOvPXfXkf3TVU3ZL0vBKAL19trf8sooHGLEt4VkanN8BRX08qg priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELaWRUhcEG8Cu8hI3CDQ-BHbB4QA7WqFBCcq7S3qJE6JlE2haRHdO_-bGTspKpS9VGo9Vh3PTDxjf_6GseemoqC9NKnW1lGCUqfgjUuNrXNXgbSlo4vCnz7nZ1P18VyfH7Cx3NEwgf3e1I7qSU2X7auf3zdv0eHfxCvj9nWPixBdFBNZisu9c-nlNXY9nBcRlG8I9yPXt3Aqc8Pdmf1dd9anQOOPq07XNPsi0H-BlH-dpoZF6vQ2uzVEl_xdNIc77MB3d9mNWG9yc4_9OulaQn5XfN5uSoLF8x-YK0eq7g1vOt6v23rEqqcBhI7CtL-XDpj2Fr_Tti0XPG7bNmXPmypijrCNcPRzTsJNt16sez5g4vlFeHnQsO-z6enJlw9n6VCHIS1zK1epBmmUroTNZ2AzIyuJMV7tndRQA74jakUkdxKDqdIJL7WHus4qN_PYy5XWywfssFt0_hHjmYcZaC8nJYByVB_USjupfF7ltQAPCcvG2S_KgaScamW0RTgsl7aIGitQY0XQWHGZsBfbPt8iRceV0u9JqVtJotcOPyyW82Lw1gJAgBQTMGAmCqoMvJYzjJbAO4qAdcKO0SRwhPSZWUOkdYoARphuYoKmEnY0GksxmnSBia4ylDGKhD3bNqM30xHNrPOoE5IhRkShbcIeRtvajlTKXDnp8M_NjtXtPMpuS9d8DYzhxglKRRP2crTPP8P6_1Q9vvopnrCbghwnAPKO2OFqufbHGKGt4Glwu99rcTfE priority: 102 providerName: Scholars Portal – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwED6NTki8IH6TsSEj8QYRiR3H9mNBm6ZK8AKT9hblEqdEKilaW6Tunf97d05SVBhIvFRqfVYvubPvzv78GeC1qTlpr0ystXVcoDQxeuNiY5vc1ahs5fig8MdP-flFNrvUlwcgx7MwAbQfKC3DND2iw96tKNDwYTCZxhTSnYuv78ChNTT9TuBwOp19nu1WVnjvKkvdcEImUfaWzntRKJD1U2zp2va2PPNPuORve6YhFJ09gPtDDimmvdYP4cB3j-Buf6vk9jH8PO0WjO-uxXyxrRj8Ln5QRdwTcm9F24nVZtGMiPQ4QM1JmFfx4gG5vqDvvDgrpOgXZ9tqJdq6RxZRG6Pl54KF226z3KzEgHwX38IUwWo_gYuz0y8fzuPhtoW4yq1axxqVyXQtbV6iTY2qFWVyjXdKY4M0EzQZU9kpSpkqJ73SHpsmrV3pqZerrFdPYdItO_8cROqxRO1VUiFmjm8Btcomtc_rvJHoMYJ0fPtFNVCR840YiyJsiStb9BYryGJFsFhxHcGbXZ_vPRHHP6Xfs1F3kkyiHX5YXs2LwakKRIlKJmjQJBnWKXqtSsqJ0DvOc3UEJ-QSpCF_ptYwNV3GMCIqKqkMyyI4Hp2lGEb-qqByNjNcF8oIXu2aaczyRkzZebIJyzDvodQ2gme9b-00VSrPnHL052bP6_YeZb-la78GXnDjJBecEbwd_fOXWn9_VUf_J_4C7kkeSAGGdwyT9dXGn1BetsaXw0C8AdA9NBs priority: 102 providerName: Springer Nature |
| Title | Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring |
| URI | https://cir.nii.ac.jp/crid/1872835442374959744 https://link.springer.com/article/10.1038/s41598-021-83999-z https://www.ncbi.nlm.nih.gov/pubmed/33649395 https://www.proquest.com/docview/2494709602 https://www.proquest.com/docview/2495407258 https://pubmed.ncbi.nlm.nih.gov/PMC7921550 https://doaj.org/article/bb2b320b7b704bd1be53a008be945655 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdby2AvY9_z1gYN9raJxpJlSU8jDSkl0DK2FfJmIkvODJnT1Ukhfe__vTtZSck--mJjS8ay7yT97vTTHSEflEPQXiompTZooFTMemWY0lVunBW6NLhR-Ow8P73IxhM5iQ63NtIqN2NiGKjdokQf-RGYCZlCvM0_X_5imDUKV1djCo2HZD8FJIKpG9REbX0suIqVpSbulekLfdTCfIV7ynjKABkYw2525qMQth9mmaau_4U4_yZO_rF6Gialk6fkSUSTdNCJ_xl54Jvn5FGXX3L9gtyOmjkyvR2dzdcl0uDpNdjGXWjuNa0b2q7m1YabzgLpHCqjP49FDvscrtFNSznt3LR12dLadRwjKEPe_Ixi5bpZLVYtjRx4-jMMFtjsl-TiZPR9eMpi3gVW5losmbRCZdJxnU-tTpVwAjBd5Y2QtrIwJlQZBrUTAJ5Kw72Q3lZV6szUw1Om1F68InvNovFvCE29nVrpRb-0NjOYD1QL3Xc-d3nFrbcJSTd_vyhjUHLMjTEvwuK40EUnsQIkVgSJFTcJ-bh95rILyXFv7WMU6rYmhtMONxZXsyL2zsJabgXvW2VVP7MutV6KKaAj6w0iXpmQQ1AJaCEeU60wSF2GhCIwL8EgyxJysFGWIo4BbXGnsQl5vy2G3otLMtPGg0ywDkZA5FIn5HWnW9uWCpFnRhh4udrRup1P2S1p6h8hQrgyHE3PhHza6Odds_7_q97e_xXvyGOOHScQ8A7I3vJq5Q8BkS1tL3S7HtkfDMbfxnA-Hp1_-Qp3h_mwF7wccDzL9G-ukjoO |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgQXxLMEWjASnCBqYsexfUCIR6stfZxaaW9mnThLpCVbml3Q9s7f4Tcyk8dWy6O3Xlba9WTjZMbjeXyeAXihcjLaMxVKqQ05KEXovDKh0kVqcid0Zuig8OFROjhJPg3lcA1-9WdhCFbZ68RGUefTjGLk2-gmJIrsbf729FtIXaMou9q30GjFYt8vfqDLVr_Z-4j8fcn57s7xh0HYdRUIs1SLWSidUInMuU5HTsdK5AItlsIbIV3hUOKLhEq2CTQNMsO9kN4VRZybkcerTKa9wP-9BtcTSjHi-lFDtYzpUNYsiU13NicServG_ZHOsPE4REvEmPB8Zf9r2gTgrlaV5b8s3L-Bmn9ka5tNcPcO3O6sV_auFbe7sOare3Cj7We5uA8_d6oJIctzNp4sMoLds-_oi7elwBesrFg9nxQ9Fj5sQO5ITPHDsMPMT_A7hYUZZ21YuMxqVuYtpgnHCKc_ZkRcVvPpvGYd5p59bZQTTfsBnFwJRx7CejWt_CNgsXcjJ72IMucSQ_1HtdBR7tM8LbjzLoC4f_s264qgUy-OiW2S8ULblmMWOWYbjtnzAF4trzltS4BcSv2emLqkpPLdzQ_Ts7HttIF1jjvBI6ecihKXx85LMUJrzHlDFrYMYAtFAmdIn7FWVBQvIQATurPoACYBbPbCYjudU9uLFRLA8-UwagtKAY0qjzwhGqq4yKUOYKOVreVMhUgTIwzeXK1I3cqjrI5U5ZemIrkynFzdAF738nkxrf-_qseXP8UzuDk4PjywB3tH-0_gFqdF1ID_NmF9djb3W2gNztzTZgky-HzVa_43F7twZQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJhAviG8CGxgJnsBqYyex_TAhxlptDKoJMWlvWRw7JVJJx9KCunf-Of4q7hKnU_nY214qtb40Tu7Dd76f7wh5IS067blkcaw0BigFM05qJlWRaGuEyjUeFP44SvaOovfH8fEa-dWdhUFYZWcTG0NtpznukfcgTIgk-tu8V3hYxOHu8M3pN4YdpDDT2rXTyHybBbvdlBvzhzwO3OIHhHP19v4u8P4l58PB53d7zHccYHmixIzFRsgotlwlmVGhFFaAN1M4LWJTGNCGIsJybgLchlxzJ2JniiK0OnNwlc6VE_C_18iGhFUfAsGNncHo8NNyxwdzalGo_cmdvlC9GlZPPOHGQwZ-itbsfGV1bJoIwJpXleW__N-_YZx_5HKbJXJ4m9zyvi192wrjHbLmqrvketvtcnGP_BxUE8SdWzqeLHIE5dPvEKm3hcIXtKxoPZ8UHVKeNRB4IMbdReYR9RP4jpvGlNN207jMa1raFvEEY4jiH1MkLqv5dF5Tj8inXxvThdO-T46uhCcPyHo1rdwjQkNnMhM70c-NiTR2J1VC9a1LbFJw40xAwu7tp7kvkY6dOiZpk6oXKm05lgLH0oZj6XlAXi2vOW0LhFxKvYNMXVJice_mh-nZOPW2IjWGG8H7RhrZj4wNjYtFBr6acRr97zggWyASMEP8DJXEknkRwpsg2IXwMArIZicsqbdIdXqhPwF5vhwGW4IJoqxywBOkwXqMPFYBedjK1nKmQiSRFhpuLlekbuVRVkeq8ktTr1xqjoFwQF538nkxrf-_qseXP8UzcgP0P_2wPzp4Qm5y1KEGGbhJ1mdnc7cFruLMPPU6SMnJVav9b3Hue0A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enlarged+glycemic+variability+in+sulfonylurea-treated+well-controlled+type+2+diabetics+identified+using+continuous+glucose+monitoring&rft.jtitle=Scientific+reports&rft.au=Uemura+Fumi&rft.au=Okada+Yosuke&rft.au=Torimoto+Keiichi&rft.au=Tanaka+Yoshiya&rft.date=2021-03-01&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-83999-z&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |